Table I.
Clinical characteristics of patients with CLL.
| A, Total number of patients. | |
|---|---|
| Variables | Patient no. (%) |
| Sex | |
| Female (%) | 29 (48.30) |
| Male (%) | 31 (51.70) |
| Rai stage | |
| 0 (%) | 24 (40.00) |
| I (%) | 17 (28.30) |
| II (%) | 7 (11.70) |
| III (%) | 8 (13.30) |
| IV (%) | 4 (6.70) |
| ZAP-70 (cut-off 20%)a | |
| Positive (%) | 28 (46.70) |
| Negative (%) | 32 (53.30) |
| CD38 (cut-off 20%)b | |
| Positive (%) | 26 (46.30) |
| Negative (%) | 34 (56.70) |
| Cytogenetic abnormalities | |
| del(17p13.1) (%) | 4 (6.70) |
| del(11q22.3) (%) | 6 (10.00) |
| Without del(17p13.1) and | 50 (83.30) |
| del(11q22.3) (%) | |
| Patients requiring therapy | 12 (20.00) |
| Untreated patients | 48 (80.00) |
| B, Median range of patient data. | |
| Variables | Median (range) |
| Age at diagnosis (years) | 67 (46–87) |
| WBC count (G/l) | 26.41 (11.96–280.46) |
| Lymphocyte count (G/l) | 19.91 (5.62–269.13) |
| β2M (mg/dl) | 2.26 (1.36–8.10) |
| LDH (IU/l) | 387.00 (287.00–839.00) |
| Hemoglobin (g/dl) | 14.20 (8.20–17.20) |
| Platelets (G/l) | 183.00 (70.00–339.00) |
| % CD19+/CD5+/ZAP-70+ cellsa | 17.02 (2.41–58.43) |
| % CD19+/CD5+/CD38+ cellsb | 10.13 (0.72–87.72) |
| % iNKT cells (Vα24-Jα18+/CD3+)c | 0.21 (0.01–1.51) |
CLL, chronic lymphocytic leukemia; WBC, white blood cell; LDH, Lactate dehydrogenase; β2M, β2-microglobulin.
a
Patients with ZAP-70 expression lower or higher than 20% were classified as ZAP-70 negative or positive, respectively.
b
Patients with CD38 expression lower or higher than 30% were classified as CD38 negative or positive, respectively.
c
% among CD3+ lymphocytes.